Results 251 to 260 of about 363,419 (348)
Back Again to the Future: A New Era for Cerebroprotection
Annals of Neurology, EarlyView.Cerebroprotection is a fresh framework for designing neurological therapy that targets glia and vascular cells, in addition to neurons. In the future, successful cerebroprotection will involve targeting all elements of the neurovascular unit. Preclinical trials must include functional outcomes, as well as lesion morphometry.
Patrick Lyden
wiley +1 more source
Immunostimulation Signaling via Toll-like Receptor 2 Activation: A Molecular Mechanism of Lactococcus lactis OTG1204 In Vitro and In Vivo. [PDF]
NutrientsSong HA +10 more
europepmc +1 more source
Age-Related Differences in Monocyte Toll-Like Receptor 2/4 and CD54 Expression in Mice [PDF]
, 2009 Breslin, Whitney L +2 more
core +1 more source
Advanced NanoBiomed Research, EarlyView.Ultrasound contrast agents, including microbubbles and nanobubbles, transform imaging and targeted therapy through precise engineering of size, shell composition, and surface properties. This review explores how these innovations enable tissue‐specific delivery, enhance therapeutic efficacy, and extend applications from vascular imaging to tumor ...
Ashkan Seza +2 more
wiley +1 more source
Therapeutic potential of a systemically applied humanized monoclonal antibody targeting Toll‑like receptor 2 in atopic‑dermatitis‑like skin lesions in a mouse model. [PDF]
Biomed RepYeo H, Jung E, Kim TY, Shin SY.
europepmc +1 more source
Advanced NanoBiomed Research, EarlyView.This review explains how biomaterials and nanoparticles can be used to induce or modulate tertiary lymphoid structures (TLSs), which are ectopic immune hubs that form in nonlymphoid tissues during chronic disease and cancer. By comparing different methods, the article highlights design principles for modeling TLSs or recapitulating specific TLS ...
Shaza Karaman, Mei ElGindi, Jeremy Teo
wiley +1 more source
Simplified scalable synthesis of a water-soluble toll-like receptor 2 agonistic lipopeptide adjuvant for use with protein-based viral vaccines. [PDF]
Bioorg ChemBrar DS +5 more
europepmc +1 more source
Toll-like receptors, session 2 (WS-001b) [PDF]
International Immunology, 2010 openaire +1 more source